Development of a Fully Cross-Validated Bayesian Network Approach for Local Control Prediction in Lung Cancer.

Bayesian networks large-scale model building local control prediction non–small-cell lung cancer pan-Omics

Journal

IEEE transactions on radiation and plasma medical sciences
ISSN: 2469-7311
Titre abrégé: IEEE Trans Radiat Plasma Med Sci
Pays: United States
ID NLM: 101705223

Informations de publication

Date de publication:
Mar 2019
Historique:
entrez: 12 3 2019
pubmed: 12 3 2019
medline: 12 3 2019
Statut: ppublish

Résumé

The purpose of this study is to demonstrate that a Bayesian network (BN) approach can explore hierarchical biophysical relationships that influence tumor response and predict tumor local control (LC) in non-small-cell lung cancer (NSCLC) patients before and during radiotherapy from a large-scale dataset. Our BN building approach has two steps. First, relevant biophysical predictors influencing LC before and during the treatment are selected through an extended Markov blanket (eMB) method. From this eMB process, the most robust BN structure for LC prediction was found via a wrapper-based approach. Sixty-eight patients with complete feature information were used to identify a full BN model for LC prediction before and during the treatment. Fifty more recent patients with some missing information were reserved for independent testing of the developed pre- and during-therapy BNs. A nested cross-validation (N-CV) was developed to evaluate the performance of the two-step BN approach. An ensemble BN model is generated from the N-CV sampling process to assess its similarity with the corresponding full BN model, and thus evaluate the sensitivity of our BN approach. Our results show that the proposed BN development approach is a stable and robust approach to identify hierarchical relationships among biophysical features for LC prediction. Furthermore, BN predictions can be improved by incorporating during treatment information.

Identifiants

pubmed: 30854500
doi: 10.1109/TRPMS.2018.2832609
pmc: PMC6404542
mid: NIHMS1003249
doi:

Types de publication

Journal Article

Langues

eng

Pagination

232-241

Subventions

Organisme : NCI NIH HHS
ID : P01 CA059827
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA142840
Pays : United States

Références

Am J Clin Oncol. 2002 Feb;25(1):76-80
pubmed: 11823702
Ernst Schering Res Found Workshop. 2004;(45):53-8
pubmed: 14699793
AMIA Annu Symp Proc. 2003;:21-5
pubmed: 14728126
Science. 2005 Apr 22;308(5721):523-9
pubmed: 15845847
Nature. 2005 Jun 9;435(7043):839-43
pubmed: 15944709
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):324-33
pubmed: 16168827
Cancer Treat Res. 2005;126:15-44
pubmed: 16209061
Clin Cancer Res. 2006 Apr 15;12(8):2545-54
pubmed: 16638864
Bioinformatics. 2006 Jul 15;22(14):e184-90
pubmed: 16873470
Carcinogenesis. 2007 Jul;28(7):1437-41
pubmed: 17361014
Comput Biol Med. 2007 Nov;37(11):1553-64
pubmed: 17434159
Cancer Sci. 2007 Jul;98(7):1048-54
pubmed: 17511773
Med Phys. 2007 Dec;34(12):4738-49
pubmed: 18196801
J Biomed Inform. 2008 Apr;41(2):242-50
pubmed: 18262472
J Natl Cancer Inst. 1991 Mar 20;83(6):417-23
pubmed: 1847977
Neoplasia. 2009 Mar;11(3):228-36
pubmed: 19242604
Clin Cancer Res. 2009 Apr 15;15(8):2647-56
pubmed: 19351767
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Med Phys. 2010 Apr;37(4):1401-7
pubmed: 20443461
Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):57-69
pubmed: 21068203
J Nucl Med. 2011 Mar;52(3):369-78
pubmed: 21321270
Phys Med Biol. 2011 Mar 21;56(6):1635-51
pubmed: 21335651
J Biomed Inform. 2011 Oct;44(5):859-68
pubmed: 21642013
Mol Oncol. 2012 Apr;6(2):211-21
pubmed: 22381063
J Thorac Oncol. 2012 Apr;7(4):716-22
pubmed: 22425920
Ann Surg Oncol. 2013 Jan;20(1):161-74
pubmed: 22899001
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e217-22
pubmed: 22935395
Clin Exp Metastasis. 2013 Apr;30(4):393-405
pubmed: 23143679
Eur J Nucl Med Mol Imaging. 2013 May;40(5):716-27
pubmed: 23340594
PLoS One. 2013 Dec 06;8(12):e82349
pubmed: 24324773
BMC Cancer. 2013 Dec 27;13:607
pubmed: 24369748
J Thorac Dis. 2014 Apr;6(4):336-47
pubmed: 24688778
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Oncoscience. 2014 Nov 15;1(11):674-705
pubmed: 25593996
BMC Bioinformatics. 2015;16 Suppl 4:S7
pubmed: 25734576
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
Sci Rep. 2015 Jun 05;5:11044
pubmed: 26251068
Tumour Biol. 2016 Jan;37(1):115-25
pubmed: 26563372
J Nucl Med. 2016 Jun;57(6):842-8
pubmed: 26912429
J Gene Ther. 2016 Feb;2(1):null
pubmed: 27376157
J Immunol Res. 2016;2016:6530410
pubmed: 27446967
Methods. 2016 Dec 1;111:32-44
pubmed: 27586524
Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8433-E8442
pubmed: 27956623
Radiother Oncol. 2017 Apr;123(1):85-92
pubmed: 28237401
Aging (Albany NY). 2017 Mar 8;9(3):852-859
pubmed: 28275206
Oncotarget. 2017 Jun 20;8(25):40946-40957
pubmed: 28402963
PLoS One. 2017 Jun 6;12(6):e0178843
pubmed: 28586353
Cancer Res. 1967 Feb;27(2):209-20
pubmed: 6018555
Cancer. 1980 Jun 1;45(11):2744-53
pubmed: 6991092
J Neurosurg. 1995 May;82(5):874-8
pubmed: 7714614
J Exp Med. 1995 Mar 1;181(3):1211-6
pubmed: 7869037
Med Phys. 1997 Jan;24(1):103-10
pubmed: 9029544

Auteurs

Yi Luo (Y)

Department of Radiation Oncology, University of Michigan, Ann Arbor, USA, yiyiLuo@med.umich.edu.

Daniel McShan (D)

Department of Radiation Oncology, University of Michigan, Ann Arbor, USA.

Dipankar Ray (D)

Department of Radiation Oncology, University of Michigan, Ann Arbor, USA.

Martha Matuszak (M)

Department of Radiation Oncology, University of Michigan, Ann Arbor, USA.

Shruti Jolly (S)

Department of Radiation Oncology, University of Michigan, Ann Arbor, USA.

Theodore Lawrence (T)

Department of Radiation Oncology, University of Michigan, Ann Arbor, USA.

Feng Ming Kong (F)

Department of Radiation Oncology, Indiana University, Indianapolis, USA.

Randall Ten Haken (R)

Department of Radiation Oncology, University of Michigan, Ann Arbor, USA.

Issam El Naqa (I)

Department of Radiation Oncology, University of Michigan, Ann Arbor, USA.

Classifications MeSH